Impact of modelling intra‐subject variability on tests based on non‐linear mixed‐effects models in cross‐over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients
- 30 June 2006
- journal article
- Published by Wiley in Statistics in Medicine
- Vol. 26 (6) , 1268-1284
- https://doi.org/10.1002/sim.2622
Abstract
We evaluated the impact of modelling intra‐subject variability on the likelihood ratio test (LRT) and the Wald test based on non‐linear mixed effects models in pharmacokinetic interaction and bioequivalence cross‐over trials. These tests were previously found to achieve a good power but an inflated type I error when intra‐subject variability was not taken into account. Trials were simulated under H0 and several H1 and analysed with the NLME function. Different configurations of the number of subjects n and of the number of samples per subject J were evaluated for pharmacokinetic interaction and bioequivalence trials. Assuming intra‐subject variability in the model dramatically improved the type I error of both interaction tests. For the Wald test, the type I error decreased from 22, 14 and 7.7 per cent for the original (n = 12, J = 10), intermediate (n = 24, J = 5) and sparse (n = 40, J = 3) designs, respectively, down to 7.5, 6.4 and 3.5 per cent when intra‐subject variability was modelled. The LRT achieved very similar results. This improvement seemed mostly due to a better estimation of the standard error of the treatment effect. For J = 10, the type I error was found to be closer to 5 per cent when n increased when modelling intra‐subject variability. Power was satisfactory for both tests. For bioequivalence trials, the type I error of the Wald test was 6.4, 5.7 and 4.2 per cent for the original, intermediate and sparse designs, respectively, when modelling intra‐subject variability. We applied the Wald test to the pharmacokinetic interaction of tenofovir on atazanavir, a novel protease inhibitor. A significant decrease of the area under the curve of atazanavir was found when patients received tenofovir. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 13 references indexed in Scilit:
- Evaluation by simulation of tests based on non‐linear mixed‐effects models in pharmacokinetic interaction and bioequivalence cross‐over trialsStatistics in Medicine, 2005
- Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected PatientsAntimicrobial Agents and Chemotherapy, 2004
- Enhanced Saquinavir Exposure in Human Immunodeficiency Virus Type 1-Infected Patients with Diarrhea and/or Wasting SyndromeAntimicrobial Agents and Chemotherapy, 2004
- Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population PharmacokineticsJournal of Biopharmaceutical Statistics, 2003
- Increased oral ganciclovir bioavailability in HIV‐infected patients with chronic diarrhoea and wasting syndrome—a population pharmacokinetic studyBritish Journal of Clinical Pharmacology, 2001
- Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test.Journal of Pharmacokinetics and Pharmacodynamics, 2001
- Oral Ganciclovir Systemic Exposure Is Enhanced in HIV-Infected Patients With Diarrhea and Weight LossJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Oral Ganciclovir Systemic Exposure Is Enhanced in HIV-Infected Patients With Diarrhea and Weight LossJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Bioequivalence trials, intersection-union tests and equivalence confidence setsStatistical Science, 1996